Future of FMT for recurrent C. difficile infection still unclear

Future of FMT for recurrent C. difficile infection still unclear

Fecal microbiota transplantation is not yet FDA approved for treating recurrent Clostridioides difficile despite several studies showing it to be efficacious and safe.Currently, FMT exists under a policy of enforcement discretion of the FDA, allowing it to be used for the treatment of C. difficile.In a study conducted by Colleen R. Kelly, MD, and colleagues, FMT cured C. difficile in 90% of patients in the FMT National Registry, which included 20 FMT practice sites in North America. Safety and efficacy were similar between real-world experience and research studies. After 6 months follow upRead More

Share on facebook
Share on twitter
Share on linkedin